U.S. Markets open in 4 hrs 3 mins

Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research
PulteGroup (PHM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AEterna Zentaris (AEZS) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

AEterna Zentaris is one of 840 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AEZS is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for AEZS's full-year earnings has moved 780% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Our latest available data shows that AEZS has returned about 19.92% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -4.71% on a year-to-date basis. As we can see, AEterna Zentaris is performing better than its sector in the calendar year.

Breaking things down more, AEZS is a member of the Medical - Biomedical and Genetics industry, which includes 340 individual companies and currently sits at #76 in the Zacks Industry Rank. On average, this group has lost an average of 21.96% so far this year, meaning that AEZS is performing better in terms of year-to-date returns.

AEZS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AEterna Zentaris Inc. (AEZS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research